Shots:

• AbCellera to receive upfront- pre-clinical- clinical & commercial milestones including research payments for the non-COVID-19 targets plus royalties on future sales. Eli Lilly to get rights to develop and commercialize the Abs developed in the collaboration
• In early 2020- the companies collaborated for multi target agreement focusing to develop Abs for COVID-19 while Eli Lilly will select 8 additional targets to develop Abs utilizing AbCellera’s antibody drug discovery platform against up to nine targets
• Additionally- AbCellera partners with multiple biotech and pharma companies completing 55 programs while transforming the field of biologics reducing the time it takes to identify lead candidates and advance new products towards the clinic

Click here ­to­ read full press release/ article 

Ref: AbCellera | Image: Eli Lilly